RAPT Price To Sales Ratio vs Capex To Depreciation Analysis

RAPT Stock

USD 30.14 1.04 3.57%

RAPT Therapeutics financial indicator trend analysis is much more than just breaking down RAPT Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether RAPT Therapeutics is a good investment. Please check the relationship between RAPT Therapeutics Price To Sales Ratio and its Capex To Depreciation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

Price To Sales Ratio vs Capex To Depreciation

Price To Sales Ratio vs Capex To Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of RAPT Therapeutics Price To Sales Ratio account and Capex To Depreciation. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between RAPT Therapeutics' Price To Sales Ratio and Capex To Depreciation is -0.23. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Depreciation in the same time period over historical financial statements of RAPT Therapeutics, assuming nothing else is changed. The correlation between historical values of RAPT Therapeutics' Price To Sales Ratio and Capex To Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of RAPT Therapeutics are associated (or correlated) with its Capex To Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Depreciation has no effect on the direction of Price To Sales Ratio i.e., RAPT Therapeutics' Price To Sales Ratio and Capex To Depreciation go up and down completely randomly.

Correlation Coefficient

-0.23

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing RAPT Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on RAPT Therapeutics sales, a figure that is much harder to manipulate than other RAPT Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Capex To Depreciation

The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.

Most indicators from RAPT Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into RAPT Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RAPT Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.Sales General And Administrative To Revenue is likely to gain to 12.53 in 2025, whereas Selling General Administrative is likely to drop slightly above 16.7 M in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	87.3M	127.1M	136.1M	81.4M
Cost Of Revenue	2.8M	3.6M	4.1M	2.1M

Total Operating Expenses Cost Of Revenue

RAPT Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		-0.81	0.6	0.69	0.95	0.87	0.93	0.8	-0.76	-0.86	0.62	0.36	0.82	0.79	0.6	1.0	0.94	0.92	-0.77	0.93	0.6	0.96	-0.68	0.95	0.76	1.0
Short Long Term Debt Total	-0.81		-0.57	-0.67	-0.82	-0.94	-0.92	-0.61	0.88	0.79	-0.57	-0.34	-0.64	-0.67	-0.35	-0.81	-0.8	-0.84	0.75	-0.89	-0.84	-0.83	0.68	-0.82	-0.62	-0.81
Other Current Liab	0.6	-0.57		0.99	0.54	0.53	0.75	0.39	-0.86	-0.89	0.24	0.93	0.34	0.14	-0.15	0.61	0.61	0.71	-0.51	0.78	0.35	0.69	-0.36	0.54	0.66	0.61
Total Current Liabilities	0.69	-0.67	0.99		0.64	0.64	0.83	0.51	-0.91	-0.94	0.36	0.88	0.45	0.25	-0.08	0.69	0.69	0.79	-0.6	0.86	0.44	0.77	-0.46	0.64	0.73	0.69
Total Stockholder Equity	0.95	-0.82	0.54	0.64		0.91	0.9	0.81	-0.75	-0.82	0.66	0.32	0.82	0.79	0.57	0.95	0.97	0.9	-0.92	0.9	0.74	0.95	-0.87	1.0	0.71	0.95
Other Liab	0.87	-0.94	0.53	0.64	0.91		0.9	0.65	-0.82	-0.79	0.61	0.29	0.66	0.69	0.38	0.87	0.9	0.9	-0.86	0.88	0.88	0.9	-0.79	0.91	0.68	0.87
Net Tangible Assets	0.93	-0.92	0.75	0.83	0.9	0.9		0.75	-0.91	-0.95	0.66	0.52	0.77	0.72	0.36	0.92	0.91	0.95	-0.79	1.0	0.69	0.94	-0.69	0.9	0.79	0.93
Property Plant And Equipment Net	0.8	-0.61	0.39	0.51	0.81	0.65	0.75		-0.53	-0.71	0.83	0.23	0.98	0.82	0.49	0.79	0.77	0.79	-0.7	0.77	0.35	0.8	-0.66	0.81	0.8	0.79
Net Debt	-0.76	0.88	-0.86	-0.91	-0.75	-0.82	-0.91	-0.53		0.9	-0.37	-0.74	-0.5	-0.39	-0.09	-0.76	-0.77	-0.84	0.72	-0.9	-0.7	-0.82	0.6	-0.75	-0.68	-0.76
Retained Earnings	-0.86	0.79	-0.89	-0.94	-0.82	-0.79	-0.95	-0.71	0.9		-0.61	-0.7	-0.69	-0.56	-0.15	-0.86	-0.87	-0.94	0.73	-0.97	-0.52	-0.93	0.6	-0.82	-0.87	-0.86
Accounts Payable	0.62	-0.57	0.24	0.36	0.66	0.61	0.66	0.83	-0.37	-0.61		-0.02	0.88	0.84	0.3	0.6	0.65	0.71	-0.6	0.67	0.35	0.67	-0.59	0.66	0.73	0.6
Cash	0.36	-0.34	0.93	0.88	0.32	0.29	0.52	0.23	-0.74	-0.7	-0.02		0.12	-0.14	-0.32	0.37	0.39	0.48	-0.36	0.55	0.17	0.46	-0.22	0.32	0.48	0.37
Non Current Assets Total	0.82	-0.64	0.34	0.45	0.82	0.66	0.77	0.98	-0.5	-0.69	0.88	0.12		0.91	0.58	0.81	0.78	0.79	-0.68	0.78	0.37	0.79	-0.65	0.82	0.77	0.81
Non Currrent Assets Other	0.79	-0.67	0.14	0.25	0.79	0.69	0.72	0.82	-0.39	-0.56	0.84	-0.14	0.91		0.7	0.78	0.76	0.73	-0.61	0.7	0.45	0.74	-0.61	0.79	0.63	0.78
Other Assets	0.6	-0.35	-0.15	-0.08	0.57	0.38	0.36	0.49	-0.09	-0.15	0.3	-0.32	0.58	0.7		0.6	0.45	0.29	-0.34	0.34	0.33	0.38	-0.39	0.57	0.06	0.59
Cash And Short Term Investments	1.0	-0.81	0.61	0.69	0.95	0.87	0.92	0.79	-0.76	-0.86	0.6	0.37	0.81	0.78	0.6		0.94	0.92	-0.76	0.93	0.6	0.96	-0.67	0.95	0.75	1.0
Common Stock Total Equity	0.94	-0.8	0.61	0.69	0.97	0.9	0.91	0.77	-0.77	-0.87	0.65	0.39	0.78	0.76	0.45	0.94		0.95	-0.9	0.91	0.68	0.98	-0.82	0.97	0.8	0.94
Common Stock Shares Outstanding	0.92	-0.84	0.71	0.79	0.9	0.9	0.95	0.79	-0.84	-0.94	0.71	0.48	0.79	0.73	0.29	0.92	0.95		-0.8	0.96	0.6	0.99	-0.69	0.9	0.92	0.92
Non Current Liabilities Total	-0.77	0.75	-0.51	-0.6	-0.92	-0.86	-0.79	-0.7	0.72	0.73	-0.6	-0.36	-0.68	-0.61	-0.34	-0.76	-0.9	-0.8		-0.79	-0.8	-0.84	0.98	-0.92	-0.62	-0.76
Capital Surpluse	0.93	-0.89	0.78	0.86	0.9	0.88	1.0	0.77	-0.9	-0.97	0.67	0.55	0.78	0.7	0.34	0.93	0.91	0.96	-0.79		0.65	0.95	-0.69	0.9	0.81	0.93
Other Current Assets	0.6	-0.84	0.35	0.44	0.74	0.88	0.69	0.35	-0.7	-0.52	0.35	0.17	0.37	0.45	0.33	0.6	0.68	0.6	-0.8	0.65		0.63	-0.8	0.74	0.28	0.61
Other Stockholder Equity	0.96	-0.83	0.69	0.77	0.95	0.9	0.94	0.8	-0.82	-0.93	0.67	0.46	0.79	0.74	0.38	0.96	0.98	0.99	-0.84	0.95	0.63		-0.73	0.95	0.87	0.96
Total Liab	-0.68	0.68	-0.36	-0.46	-0.87	-0.79	-0.69	-0.66	0.6	0.6	-0.59	-0.22	-0.65	-0.61	-0.39	-0.67	-0.82	-0.69	0.98	-0.69	-0.8	-0.73		-0.87	-0.5	-0.67
Net Invested Capital	0.95	-0.82	0.54	0.64	1.0	0.91	0.9	0.81	-0.75	-0.82	0.66	0.32	0.82	0.79	0.57	0.95	0.97	0.9	-0.92	0.9	0.74	0.95	-0.87		0.71	0.95
Property Plant And Equipment Gross	0.76	-0.62	0.66	0.73	0.71	0.68	0.79	0.8	-0.68	-0.87	0.73	0.48	0.77	0.63	0.06	0.75	0.8	0.92	-0.62	0.81	0.28	0.87	-0.5	0.71		0.75
Total Current Assets	1.0	-0.81	0.61	0.69	0.95	0.87	0.93	0.79	-0.76	-0.86	0.6	0.37	0.81	0.78	0.59	1.0	0.94	0.92	-0.76	0.93	0.61	0.96	-0.67	0.95	0.75

Click cells to compare fundamentals

RAPT Therapeutics Account Relationship Matchups

RAPT Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	119.0M	198.6M	266.2M	173.3M	240.3M	165.3M
Other Current Liab	5.3M	6.6M	6.5M	14.2M	44.7M	46.9M
Total Current Liabilities	11.7M	9.6M	14.2M	21.8M	48.4M	50.8M
Total Stockholder Equity	104.2M	186.4M	245.2M	147.0M	189.9M	130.3M
Other Liab	969K	2.2M	3.0M	2.7M	3.1M	2.2M
Net Tangible Assets	73.1M	104.2M	186.4M	245.2M	281.9M	296.0M
Property Plant And Equipment Net	3.0M	2.7M	9.5M	7.7M	4.7M	5.1M
Net Debt	(24.9M)	(24.0M)	(30.0M)	(40.6M)	(165.2M)	(157.0M)
Retained Earnings	(214.8M)	(284.0M)	(367.9M)	(484.7M)	(614.5M)	(583.8M)
Accounts Payable	2.4M	2.0M	3.4M	5.2M	1.3M	2.5M
Cash	24.9M	24.0M	38.9M	47.5M	169.7M	178.2M
Non Current Assets Total	3.4M	5.7M	13.5M	11.5M	5.1M	6.9M
Cash And Short Term Investments	111.5M	189.7M	249.1M	158.9M	231.1M	155.2M
Common Stock Shares Outstanding	24.1M	27.4M	32.5M	38.3M	40.8M	29.8M
Liabilities And Stockholders Equity	119.0M	198.6M	266.2M	173.3M	240.3M	165.3M
Non Current Liabilities Total	3.0M	2.7M	6.8M	4.5M	2.1M	2.0M
Capital Surpluse	235.0M	319.2M	470.6M	613.1M	705.0M	740.3M
Other Current Assets	8.2M	6.6M	3.6M	2.9M	4.2M	4.6M
Other Stockholder Equity	319.2M	470.6M	613.1M	631.6M	804.4M	451.2M
Total Liab	14.8M	12.3M	21.0M	26.3M	50.4M	25.5M
Net Invested Capital	104.2M	186.4M	245.2M	147.0M	189.9M	130.3M
Property Plant And Equipment Gross	3.0M	2.7M	9.5M	17.0M	14.8M	7.8M
Total Current Assets	115.6M	193.0M	252.7M	161.8M	235.2M	158.4M
Accumulated Other Comprehensive Income	(177K)	(206K)	(26K)	103K	50K	52.5K
Net Working Capital	103.9M	183.4M	238.5M	139.9M	186.9M	141.5M
Property Plant Equipment	3.7M	3.0M	2.7M	2.5M	2.3M	2.4M
Short Term Debt	4.9M	6.3M	4.3M	2.4M	2.4M	3.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC